NICE approval for Janssen’s Darzalex combination
Recommendation concerns routine use across the NHS as therapy for multiple myeloma
Read More
Tag: Darzalex
NICE ‘no’ for Janssen’s Darzalex combo
Draft guidance shows concerns on cost-effectiveness of treatment
Read More
SMC kicks off the new year by accepting five new medicines for NHS use
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Read More
US expand use of Janssen’s Darzalex
The approval broadens the drug’s label to include fifth treatment option in the relapsed/refractory multiple myeloma setting
Read More
Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study
Subcutaneous formulation of Darzalex in combination with pomalidomide and dexamethasone meets primary endpoint
Read More
Darzalex EU nod marks first newly diagnosed MM treatment in six years
The approval was based on results from part one of the Phase III CASSIOPEIA study.
Read More
More good news for Janssen’s Darzalex
The drug has hit survival and disease progression targets in Phase III trials
Read More
Darzalex, Ibrance among latest SMC decisions
The Scottish Medicines Consortium (SMC) has announced its latest round of decisions for NHS Scotland, publishing advice accepting three new medicines.
Read More
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More
Janssen presents positive Darzalex results at ASCO
The drug showed non-inferior efficacy and a significantly higher complete response rate in two different trials.
Read More
NICE u-turn backs use of Darzalex combo for myeloma relapse
Myeloma patients in England are set to gain NHS access to a new second-line treatment combination following a first relapse of the disease.
Read More
Janssen unveils new data backing wider use of Darzalex
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
